BPMC - Blueprint Medicines Corporation - Stock Price & Catalysts • BiopharmIQ

BiopharmIQ

Try Pro Free Already have an account? Login

Enterprise Value

2.925B

Cash

822.2M

Avg Qtr Burn

-123.1M

Short % of Float

7.99%

Insider Ownership

0.74%

Institutional Own.

-

Qtr Updated

03/31/23

Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
AYVAKIT (avapritinib) Details PDGFRA mutant GIST (Gastrointestinal Stromal Tumors)	Approved Quarterly sales	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
(AYVAKIT®) (avapritinib) Details Systemic Mastocytosis	Approved Quarterly sales	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
GAVRETO (parlsetinib) Details RET+ NSCLC (Non-small cell lung cancer), RET+ Thyroid cancer, solid tumors	Approved Quarterly sales	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
AYVAKIT (avapritinib) Details Systemic Mastocytosis	Approved Quarterly sales	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
BLU-451 Details Solid tumor/s, Non-small cell lung carcinoma, Cancer	Phase 1/2 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
BLU-945 +/- osimertinib Details Solid tumor/s, Non-small cell lung carcinoma, Cancer	Phase 1/2 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
BLU-222 (CDK12) Details Cancer, Breast cancer	Phase 1/2 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.